Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Life Sciences
Research results from Tufts University, Tufts Center for the Study of Drug Development update knowledge of pediatric in children
January 25th, 2009
Researchers detail in 'The economics of pediatric formulation development for off-patent drugs,' new data in life sciences. According to recent research from the United States, "Many drugs currently used in children have never been adequately studied in rigorous scientific trials. Although these medications can still be prescribed in the pediatric setting, they are considered 'off-label' because they are not specifically approved for use in children." "The role of the Economics Working Group (EWG) within the Pediatric Formulation Initiative (PFI) of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is to identify economic...
Source: Medical Letter on the CDC & FDA (2009-01-25)
|
